Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329287 | 0.92 | P2RY12 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL32676321 | 0.92 | P2RY12 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL6061162 | 0.89 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL31682533 | 0.88 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31744966 | 0.86 | P2RY12 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL31745004 | 0.86 | P2RY12 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL15329230 | 0.85 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21314871 | 0.85 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL22605126 | 0.85 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 | |
| SCHEMBL22605125 | 0.85 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12516322-B2 | Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12503699-B2 | Compositions and methods for silencing UGT1a1 gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12473550-B2 | Coagulation factor V (F5) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-9376680-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | SLC28A1 2582/4885SLC28A2 2337/4885SLC29A1 2372/4885 |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFH, SSB, RNASEH1 | SLC28A1 1642/4885SLC28A2 1917/4885SLC29A1 2177/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | SLC28A1 1308/4885SLC28A2 1199/4885SLC29A1 982/4885 |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ADAR, RNASEH1, NSUN2 | SLC28A1 794/4885SLC28A2 911/4885SLC29A1 429/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | SLC28A1 972/4885SLC28A2 506/4885SLC29A1 1088/4885 |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | POLM, PCNA, POLRMT | SLC28A1 1890/4885SLC28A2 1888/4885SLC29A1 1613/4885 |
| US-12473550-B2 | Coagulation factor V (F5) iRNA compositions and methods of use thereof | F5, F13B, F12 | SLC28A1 4409/4885SLC28A2 4480/4885SLC29A1 3675/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | SLC28A1 10/4885SLC28A2 6/4885SLC29A1 86/4885 |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ATXN2, ATXN2L, ATXN10 | SLC28A1 2535/4885SLC28A2 2362/4885SLC29A1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.